CAR T-cell therapies represent one of the most significant technical advances in the treatment of malignancies of the past decade. Given the complexity of CAR T-cell development, manufacture, testing and, ultimately, clinical use, it is important this technology has stringent regulations and guidance. In this article, we share how to address the communication challenges unique to this therapy.
Download the white paper below
